Key Benefits:
In the "Official Gazette of the State" of 20 November 2010 and the "Official Gazette of the Junta de Andalucía" of 19 November 2010, the publication of the Resolution of October 18, 2010, of the University of São Paulo, was carried out. de Olavide, from Seville, for which the curriculum of the Master's degree in "Health Biotechnology" was made public.
According to the provisions of Article 28 of Royal Decree 861/2010 of 2 July 2010 amending Royal Decree 1393/2007 of 29 October establishing the ordination of university teaching Official, Pablo de Olavide University of Seville, proposed to the Ministry of Education a change in the curriculum of the aforementioned Master.
Having received a favorable report from the National Agency for the Evaluation of Quality and Accreditation (ANECA) for not affecting changes in the curriculum of such a Master to nature, nor to the objectives of the title registered in the Register of Universities, Centers and Titles (RUCT),
This Rectorate has resolved:
Order the publication of the new study plan leading to the obtaining of the official university Master's degree in "Health Biotechnology".
The curriculum referred to in this resolution shall be structured as set out in the Annex.
Sevilla, April 20, 2012. -El Rector, Juan Jiménez Martínez.
ANNEX
Plan of studies leading to the degree of university degree in "Health Biotechnology" (Royal Decree 1393/2007, Annex I, section 5.1). Structure of the teachings)
Distribution of the curriculum in ECTS credits, by type of subject
| ECTS | |
|---|---|
|
|
35 |
|
Optives | 37 |
|
Practices | - |
|
Work Master | 18 |
|
Credits | 90 |
* 12 ECTS of optional external practices are contemplated.
Overview of the curriculum
| Character | C. | |||||
|---|---|---|---|---|---|---|
|
molecular bases: |
|
| ||||
|
OBL | 2.5 | |||||
| 2.5 | ||||||
| OBL | ||||||
| OBL | ||||||
| OBL | OBL |
| ||||
| OBL | 2.5 | |||||
|
diseases |
| 2.5 | ||||
| Methods in Study and Analysis of Pathologies |
5 | |||||
| Pathogenesis and Infectious disease diagnosis | OPT | 5 | ||||
|
and research technology in biomedicine: |
|
| ||||
|
Genomics applied |
5 | 5 | ||||
| OBL | 5 | |||||
| 5 | ||||||
| 5 | OPT | 5 | OPT | |||
| Omics applied to biomedicine | OPT | 5 | ||||
| Application of model organisms in health biotechnology: |
|
| ||||
|
OBL | 5 | |||||
| tissue differentiation and morphogenesis | OPT | |||||
| regeneration | OPT | 5 | ||||
|
New Drug Generation Strategy: |
|
| ||||
|
| OPT | OPT | ||||
| Therapy | OPT | 5 | ||||
| OPT | 5 | 5 | ||||
| . course |
|
| ||||
| Professional and business training in biotechnology: |
|
| ||||
| OPT | 5 | |||||
| 5 | ||||||
| 12 | OPT | |||||
|
Biotechnology research training: |
|
| ||||
| OPT | 12 | |||||
|
of Master Job: |
|
| ||||
|
OBL | 18 |
* This matter is delivered in the first course.
